Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
---|---|---|---|---|---|
DL4-H5255 | Human | Human DLL4 Protein, Fc Tag, premium grade |
|
||
RES-A022 | Human | resDetect™ Biotinylated Human DLL4 ELISA Kit (Residue Testing) | |||
RES-A052 | Human | resDetect™ Human Fc Tag DLL4 ELISA KIT (Residue Testing) | |||
GMP-DL4H28 | Human | GMP Human DLL4 Protein, Fc Tag |
|
||
GMP-DL4H23 | Human | GMP Biotinylated Human DLL4 Protein, His,Avitag™ |
|
||
MBS-C013 | Human | ActiveMax® Human DLL4 μBeads, premium grade (for cells) | |||
CEA-B038 | Human | ClinMax™ Human Soluble Delta Like Protein 4 (DLL4) ELISA Kit, PRO | |||
DL4-H82E6 | Human | Biotinylated Human DLL4 Protein, His,Avitag™, premium grade |
|
||
DL4-H5227 | Human | Human DLL4 Protein, His Tag |
|
||
DL4-H5259 | Human | Human DLL4 Protein, Fc Tag (MALS & SPR verified) |
|
Human DLL4 Protein, Fc Tag, premium grade (Cat. No. DL4-H5255) captured on Protein A Chip can bind Human NOTCH1 Protein, His Tag, premium grade (Cat. No. NO1-H52H3) with an affinity constant between 1.00 nM - 150 nM as determined in a SPR assay (Biacore 8K) (QC tested).
GMP Human DLL4 Protein, Fc Tag (Cat. No. GMP-DL4H28) captured on Protein A Chip can bind Human NOTCH1 Protein, His Tag, premium grade (Cat. No. NO1-H52H3) with an affinity constant between 1.00 nM - 150 nM as determined in a SPR assay (Biacore 8K) (QC tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
TR-009 | NOV-1501; ABL001-ABL Bio; ABL-001-ABL Bio; ES-104; CTX-009; HD-B001A; HDB001A; TR-009 | Phase 3 Clinical | Abl Bio Inc | Biliary Tract Neoplasms; Solid tumours; Rectal Neoplasms; Colonic Neoplasms; Neoplasms; Cholangiocarcinoma; Bile Duct Neoplasms; Colorectal Neoplasms; Gallbladder Neoplasms | Details |
Navicixizumab | OMP-305B83 | Phase 3 Clinical | Oncomed Pharmaceuticals Inc | Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms | Details |
Dilpacimab | ABT-165; DVD-Ig ABT-165 | Phase 1 Clinical | Abbvie Inc | Solid tumours; Neoplasms | Details |
TR-009 | NOV-1501; ABL001-ABL Bio; ABL-001-ABL Bio; ES-104; CTX-009; HD-B001A; HDB001A; TR-009 | Phase 3 Clinical | Abl Bio Inc | Biliary Tract Neoplasms; Solid tumours; Rectal Neoplasms; Colonic Neoplasms; Neoplasms; Cholangiocarcinoma; Bile Duct Neoplasms; Colorectal Neoplasms; Gallbladder Neoplasms | Details |
Navicixizumab | OMP-305B83 | Phase 3 Clinical | Oncomed Pharmaceuticals Inc | Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms | Details |
Dilpacimab | ABT-165; DVD-Ig ABT-165 | Phase 1 Clinical | Abbvie Inc | Solid tumours; Neoplasms | Details |
This web search service is supported by Google Inc.